Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Inpatient IV anticoagulation therapy “prohibitively expensive”

    • 8 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Inpatient IV anticoagulation therapy “prohibitively expensive”. Pharmacoecon. Outcomes News 472, 12 (2005). https://doi.org/10.2165/00151234-200504720-00034

    Download citation


    • Warfarin
    • Outcome News
    • Thromboembolic Event
    • Unfractionated Heparin
    • Thromboembolic Complication